Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data will be collected in a forward-looking manner. This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data from patients on prior treatment will be collected retrospectively, and data from patients who will be treated later and included in the study will be collected in a prospective manner. The criteria for retrospective collection were consistent with those for prospective collection. Eligible patients will be enrolled after NGS analysis of tumor tissue and informed consent has been obtained. Information required for the study will be collected (every 3 months).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ICIs | Patients receiving in first-line immunotherapy with or without anti-angiogenic or chemotherapy |
| |
| Savolitinib | Patients receiving in first-line savolitinib treatment |
| |
| Glumetinib | Patients receiving in first-line glumetinib treatment |
| |
| Bozitinib | Patients receiving in first-line bozitinib treatment |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No treatment is included in this protocol. | Other | No drug intervention or tissue sampling will be included in this study. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Progression-Free-Survival | From the time the first patient included in the observational analysis received treatment until disease progression, death due to various causes or censored at the date of last contact | Assessed up to around 4.5 years |
| Overall Survival | From the time the first patient included in the observational analysis received treatment until death due to various causes or censored at the date of last contact | Assessed up to around 4.5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical relevance between genomic profiling and progression-free-survival | Kaplan-Meier analysis for progression-free survival, utilizing data from various genetic testing methods including NGS and FISH, to evaluate the impact of different genetic alterations. | Assessed up to around 4.5 years |
| Clinical relevance between genomic profiling and overall survival |
Not provided
Inclusion Criteria:
Exclusion Criteria:
None.
Not provided
Not provided
Not provided
Advanced lung cancer, MET gene mutations
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yongchang Zhang, MD | Contact | +8613873123436 | 7+861383123436 | zhangyongchang@csu.edu.cn |
| Nong Yang | Contact | +8613873123436 | yangnong0217@163.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hunan Province Tumor Hospital | Recruiting | Changsha | Hunan | China |
Not provided
Not provided
Not provided
Not provided
Kaplan-Meier analysis for overall survival, utilizing data from various genetic testing methods including NGS and FISH, to evaluate the impact of different genetic alterations. |
| Assessed up to around 4.5 years |
| ORR | Proportion of patients whose tumor volume shrinks to a pre-specified value (usually 30%) and who are able to maintain the minimum timeframe requirements. | Assessed up to around 4.5 years |